Brief: Celyad Oncology H1 Net Loss Narrows To EUR 14.4 Mln

Celyad Oncology SA

05/08/2022 06:00

Aug 5 (Reuters) - Celyad Oncology SA  CYAD.BR :
    * H1 OPERATING LOSS EUR 14.1 MILLION VERSUS LOSS EUR 14.9
MILLION
YEAR AGO
    * H1 NET LOSS WAS EUR 14.1 MILLION VERSUS NET LOSS OF EUR
14.9
MILLION YEAR AGO
    * AS OF JUNE 30, 2022, THE COMPANY HAD CASH AND CASH
EQUIVALENTS
OF EUR 14.4 MILLION
    * ENROLLMENT ONGOING IN PHASE 1 DOSE-ESCALATION IMMUNICY-1
TRIAL
FOR LEAD SHRNA-BASED ALLOGENEIC CAR T CANDIDATE, CYAD-211, FOR
RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)
    * ADDITIONAL DATA UPDATES FROM THE ELD COHORTS OF THE PHASE
1
IMMUNICY-1 TRIAL OF CYAD-211 FOR R/R MM EXPECTED IN H2
    * PATENTS PROVIDE AN AVENUE TO DEVELOP OWN PROGRAMS AND SEEK
POTENTIAL PARTNERSHIP OPPORTUNITIES
    * SHARC PLATFORM: DISCOVERY RESEARCH CONTINUES ON PROGRAMS
FOCUSED
ON CO-EXPRESSION OF INTERLEUKIN-18 IN CONJUNCTION WITH SHORT
HAIRPIN RNA SHRNA TECHNOLOGY PLATFORM

Source text for Eikon:  ID:nGNXbvm57c 
Further company coverage:  CYAD.BR 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))